Bellasi Antonio, Cozzolino Mario, Malberti Fabio, Cancarini Giovanni, Esposito Ciro, Genderini Augusto, Guastoni Carlo Maria, Ondei Patrizia, Pontoriero Giuseppe, Teatini Ugo, Vezzoli Giuseppe, Messa Piergiorgio, Locatelli Francesco
UOC di Nefrologia e Dialisi, Ospedale Sant'Anna, ASST-Lariana, Como.
UOC Nefrologia e Dialisi ASST Santi Paolo e Carlo, Presidio San Paolo, Milano.
G Ital Nefrol. 2018 May;35(3).
Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.
骨矿物质异常（定义为慢性肾脏病矿物质和骨异常；CKD-MBD）在慢性肾脏病患者中普遍存在，且与相当大的风险负担及不良预后相关。多条证据支持这样一种观点，即很大一部分接受维持性透析的患者，其CKD-MBD的生化指标控制欠佳。尽管尚无研究能确凿证明控制CKD-MBD与提高生存率相关，但已有越来越多的治疗手段可用于纠正骨矿物质异常。在这份伦巴第肾病专家的立场文件中，将提供CKD-MBD的最新研究状况总结以及未满足的临床需求总结。此外，本立场文件将重点关注一种新型注射用拟钙剂依特卡肽的潜在优势和缺点，该药几个月前已在意大利上市。
